IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

ibrutinib capsules

ibrutinib capsules
for oral use Initial U.S. Approval: 2013

Facts about ibrutinib capsules

Approval Date: 2013
Proprietary Name: On Request
Active Ingredient(s): Ibrutinib
Dosage Forms And Strengths: Capsules: 70 mg and 140 mg
Tablets: 140 mg, 280 mg, 420 mg, and 560 mg
Oral suspension: 70 mg/mL
Companies: AbbVie, Johnson & Johnson
Diseases: Imbruvica is indicated for chronic lymphocytic leukemia (CLL), chronic lymphocytic leukemia (CLL) with 17p deletion, Waldenström’s macroglobulinemia (WM) and mantle cell lymphoma (MCL) who have received at least one prior treatment
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “ibrutinib capsules” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398

EMAIL ID:
info@indianpharmanetwork.co.in

FAX NUMBER:
+91-11-26532129

Query For ibrutinib capsules

Approved accessible "ibrutinib capsules"

Imbruvica is a medicine for treating adult patients with the following blood cancers:

  • mantle cell lymphoma (MCL) in patients whose disease does not respond to or has come back after previous treatment;
  • chronic lymphocytic leukaemia (CLL) in both previously treated and untreated patients;
  • Waldenström’s macroglobulinaemia (also known as lymphoplasmacytic lymphoma).

For the treatment of MCL, Imbruvica is taken on its own. For CLL, Imbruvica can be taken on its own but can also be taken with bendamustine and rituximab, or with either obinutuzumab, rituximab or venetoclax. For patients with Waldenström’s macroglobulinaemia, Imbruvica is taken on its own or with rituximab.

Imbruvica contains the active substance ibrutinib.

How can 1 go about obtaining ibrutinib capsules?

If ibrutinib capsules are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

IMBRUVICA (ibrutinib) capsules, for oral use Initial U.S. Approval: 2013

References

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398